Technetium (99mTc)

Radiopharmaceuticals are poised for a boom in the next decade! Analysts predict a surge in the market, driven by a perfect storm of factors. Public and private healthcare companies are pouring more money into this field, and cancer rates are rising globally. This report by FMI dives deep into why this market is thriving, what bumps it might face, and the exciting possibilities ahead. NEWARK, Del., March 25, 2024 /PRNewswire/ -- Radiopharmaceuticals is one of the most effective and newly emerged cancer treatment methodologies, which is gaining popularity in the medicare sector worldwide. With the current valuation of US$ 6,972.1 million, the Radiopharmaceuticals market is very likely to have a promising future in the coming decade. Rising incidences of cancer and cancer-associated diseases are one of the main reasons for that. Although the market is still in its nascent stages, it is slated to pick up some pace in the coming decade. With industry giants, both public as well as private, pouring billions of dollars into the development of novel radio nucleotide-including treatments, the global valuation is very likely to reach US$ 11,635 million by 2034. The industry-academia collaboration, coupled with robust government policies, hefty healthcare expenditures, increasing awareness, and rising consumer spending on well-being is responsible for the market to grow at an anticipated CAGR of 3.40% through CAGR, especially in developing and developed economies like India, China, the United States, Spain, and the United Kingdom. "The market, which is still in its nascent stages, has great opportunities in the coming future. Companies in the market must collaborate with the government to make the offerings more affordable, feasible, and available," says Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) . Key Takeaways from the Market Study The oncology segment dominates the global radiopharmaceutical market with a share of 51.40% in 2024. Based on radioisotope, the technetium-99 leads the radiopharmaceutical market with a share of 47.20% in 2024. The radiopharmaceutical market in India is anticipated to grow at a CAGR of 5.40% through 2034. The radiopharmaceutical market in Malaysia is estimated to rise at a 3.90% CAGR through 2034. The radiopharmaceutical market in Indonesia has the potential to increase at a 3.70% CAGR through 2034. The Thai radiopharmaceutical market is predicted to rise at a 3.20% CAGR through 2034. The radiopharmaceutical market in Spain is very likely to grow at a CAGR of 2.90% through 2034. Competitive Landscape The market for radiopharmaceuticals is still in its early stages with a few companies dominating the international marketplace. The requirement for radiopharmaceuticals is expected to increase significantly due to medical advancements and their wider usage in the medical world, which could provide excellent opportunities for new players to enter the market. Prominent companies in the market include Bayer AG, Bracco Imaging S.p.A., Cardinal Health, Inc., Eli Lilly and Company (Eli Lilly), Curium Pharma, Lantheus Holdings, Inc., Novartis AG, Nordion (Canada) Inc., etc. These companies provide radiopharmaceuticals to healthcare facilities such as hospitals, ambulatory surgical centers, clinics, specialty hospitals, etc. Key components in this market include innovation and keeping up with the latest medical technology. These companies are investing millions of dollars in the development of novel radiopharmaceuticals with improved efficiency. Recent Developments Bayer and PanTera partnered to obtain actinium-225 for radiopharmaceuticals, starting clinical trials in 2024. Ariceum Therapeutics opened a radiopharmaceutical lab in Berlin for R&D on upcoming pipeline candidates in March 2024. Ratio Therapeutics, in March 2024, extended its manufacturing deal with PharmaLogic to expedite production and launch of its FAP-targeted candidate. Purchase now and gain full access to the Radiopharmaceutical Industry report, featuring comprehensive Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives. About the Author: Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher. Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation. Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News. Explore FMI's Extensive Coverage in the Healthcare Domain: Cancer Diagnostics Market by Tumor Biomarkers Tests, Biopsy, Liquid Biopsy, Immunohistochemistry, In Situ Hybridization, and Other Test Types, Forecast, 2023-2033. – Review and Request to Access the Sample Report. Cancer Vaccines Market by Technology, Treatment Method, Application & Region | Forecast 2023 to 2033. - Review and Request to Access the Sample Report. Cancer Biological Therapy market by Product Type, Vehicle Type, Sales Channel & Region | Forecast 2022 to 2032. - Review and Request to Access the Sample Report. Cancer Supportive Care Products Market By Drug Class, Indication, Distribution Channel & Region - Forecast to 2020-2030. - Review and Request to Access the Sample Report. Cancer Tissue Diagnostics Market by Immunohistochemical (IHC) Test and In Situ Hybridization (ISH) Test, Forecast, 2023-2033. - Review and Request to Access the Sample Report. Cancer-Focused Genetic Testing Services Market By Test Type, Cancer Type, Service Provider & Region | Forecast 2022 to 2032. - Review and Request to Access the Sample Report. About Future Market Insights (FMI) Future Market Insights (FMI) is a leading market intelligence and consulting service provider, serving clients in over 150 countries. FMI is headquartered in Dubai and has delivery centers in the UK, the U.S., and India. FMI's latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers. Contact Us Nandini Singh Sawlani Future Market Insights Inc. Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, USA T: +1-845-579-5705 For Sales Enquiries: [email protected] Website: LinkedIn | Twitter | Blogs | YouTube Logo: SOURCE Future Market Insights

LONDON, March 15, 2024 /PRNewswire/ -- Serac Healthcare Limited ("Serac Healthcare" or "the Company"), a clinical radiopharmaceutical company developing an innovative molecular imaging agent, and the Nuffield Department of Women's and Reproductive Health at the University of Oxford announce that preliminary data has been presented from the "Detecting Endometriosis expressed integrins using technetium-99m" (DETECT) imaging study, indicating that 99mTc-maraciclatide is capable of imaging superficial peritoneal endometriosis, the earliest stage of the disease. The data was presented today by Dr Tatjana Gibbons, an investigator on the study from the University of Oxford, in an oral presentation at the Society for Reproductive Investigation (SRI) annual meeting taking place from 12-16 March 2024 in Vancouver, Canada. Serac Healthcare Logo Nuffield Department of Women's & Reproductive Health at the University of Oxford Logo